📣 VC round data is live. Check it out!

NRGene Valuation Multiples

Discover revenue and EBITDA valuation multiples for NRGene and similar public comparables like Vidavo, Biovica International, XIAO-I, Glycorex Transplantation and more.

NRGene Overview

About NRGene

NRGene Technologies Ltd is engaged in the development of artificial intelligence-based software for the analysis of genetic information in order to improve species of plants and animals.


Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

NRGene Financials

NRGene reported last fiscal year revenue of $3M and negative EBITDA of ($965K).

In the same fiscal year, NRGene generated $2M in gross profit, ($965K) in EBITDA losses, and had net loss of ($2M).


NRGene P&L

In the most recent fiscal year, NRGene reported revenue of $3M and EBITDA of ($965K).

NRGene is unprofitable as of last fiscal year, with gross margin of 61%, EBITDA margin of (30%), and net margin of (47%).

See analyst estimates for NRGene
Last FY202320242025202620272028
Revenue$3M$2M$1M$3M
Gross Profit$2M$901K$267K$2M
Gross Margin61%45%21%61%
EBITDA($965K)($5M)($3M)($965K)
EBITDA Margin(30%)(227%)(209%)(30%)
EBIT Margin(50%)(264%)(346%)(50%)
Net Profit($2M)($5M)($3M)($2M)
Net Margin(47%)(262%)(260%)(47%)

Financial data powered by Morningstar, Inc.

NRGene Stock Performance

NRGene has current market cap of $11M, and enterprise value of $6M.

Market Cap Evolution


NRGene's stock price is $0.81.

NRGene share price decreased by 3.2% in the last 30 days, and by 10.9% in the last year.

NRGene has an EPS (earnings per share) of $-0.11.

See more trading valuation data for NRGene
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$6M$11M-3.2%-3.2%-1.8%-10.9%$-0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

NRGene Valuation Multiples

NRGene trades at 1.8x EV/Revenue multiple, and (5.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for NRGene

NRGene Financial Valuation Multiples

As of June 2, 2026, NRGene has market cap of $11M and EV of $6M.

NRGene has a P/E ratio of (7.2x).

Last FY202320242025202620272028
EV/Revenue1.8x2.8x4.4x1.8x
EV/EBITDA(5.8x)(1.2x)(2.1x)(5.8x)
EV/EBIT(3.6x)(1.1x)(1.3x)(3.6x)
EV/Gross Profit2.9x6.2x21.0x2.9x
P/E(7.2x)(2.1x)(3.2x)(7.2x)
EV/FCF78.0x(1.0x)(1.1x)78.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified NRGene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

NRGene Margins & Growth Rates

In the most recent fiscal year, NRGene reported gross margin of 61%, EBITDA margin of (30%), and net margin of (47%).

See estimated margins and future growth rates for NRGene

NRGene Margins

Last FY20242025202720282029
Gross Margin61%21%61%
EBITDA Margin(30%)(209%)(30%)
EBIT Margin(50%)(346%)(50%)
Net Margin(47%)(260%)(47%)
FCF Margin2%(402%)2%

NRGene Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(36%)146%
Gross Profit Growth(70%)619%
EBITDA Growth(41%)(64%)
EBIT Growth(15%)(65%)
Net Profit Growth(36%)(55%)
FCF Growth(7%)(101%)

Data powered by FactSet, Inc. and Morningstar, Inc.

NRGene Operational KPIs

Access forward-looking KPIs for NRGene
Last FY202320242025202620272028
S&M Expenses to Revenue1%11%11%1%
G&A Expenses to Revenue20%42%53%20%
R&D Expenses to Revenue42%109%140%42%
Opex to Revenue110%309%367%110%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Vidavo3.8x-9.9x-
Biovica International2.5x1.4x(0.3x)(0.4x)
XIAO-I4.5x-(0.6x)-
Glycorex Transplantation2.7x-53.6x-
Cipia Vision----
VERSES AI----
Media Lab4.1x-13.3x-
Unith2.4x-(3.8x)-

This data is available for Pro users. Sign up to see all NRGene competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About NRGene

Where is NRGene headquartered?NRGene is headquartered in Israel.
Is NRGene publicly listed?Yes, NRGene is a public company listed on Tel Aviv Stock Exchange.
What is the stock symbol of NRGene?NRGene trades under NRGN ticker.
When did NRGene go public?NRGene went public in 2021.
Who are competitors of NRGene?NRGene main competitors include Vidavo, Biovica International, XIAO-I, Glycorex Transplantation, Cipia Vision, VERSES AI, Media Lab, Unith, VSee Health, Ayfie International.
What is the current market cap of NRGene?NRGene's current market cap is $11M.
What is the current revenue of NRGene?NRGene's last fiscal year revenue is $3M.
What is the current EV/Revenue multiple of NRGene?Current revenue multiple of NRGene is 1.8x.
Is NRGene profitable?No, NRGene is not profitable.
How many companies NRGene has acquired to date?NRGene hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies NRGene has invested to date?NRGene hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to NRGene

Lists including NRGene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial